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Abstract 
Introduction: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal 
breast cancer and approximately 20% of screen-detected tumors are pure DCIS. Most risk 
factors for breast cancer have similar associations with DCIS and IDC, however there is 
limited data on the prevalence of the known high and moderate penetrance breast cancer 
predisposition genes in DCIS and which women with DCIS should be referred for genetic 
screening. 
The aim of this study was to assess the frequency of germline variants in BRCA2, BRCA1, 
CHEK2, PALB2 and TP53 in DCIS in women aged less than 50 years of age. 
Methods: After DNA extraction from peripheral blood, Access Array technology (Fluidigm) 
was used to amplify all exons of these six known breast cancer predisposition genes using a 
custom made targeted sequencing panel in 655 cases of pure DCIS presenting in women 
under the age of 50 years together with 1,611 controls. 
Results: Case-control analysis revealed an excess of pathogenic variants in BRCA2 (OR = 
27.96, 95%CI 6.56-119.26, P = 2.0 x10-10) and CHEK2 (OR = 8.04, 95%CI 2.93-22.05, P = 
9.0 x10-6), with weaker associations with PALB2 (P = 0.003), BRCA1 (P = 0.007) and TP53 
(P = 0.02). For estrogen receptor (ER) positive DCIS the frequency of pathogenic variants 
was 9% under the age of 50 (14% with a family history of breast cancer) and 29% under the 
age of 40 (42% with a family history of breast cancer). For ER negative DCIS the frequency 
was 9% (16% with a family history of breast cancer) and 8% (11% with a family history of 
breast cancer) under the age of 50 and 40 respectively. 
Conclusions: This study has shown that breast tumorigenesis in women with pathogenic 
variants in BRCA2, CHEK2, PALB2, BRCA1 and TP53 can involve a DCIS precursor stage 
and that the focus of genetic testing in DCIS should be on women under the age of 40 with 
ER positive DCIS. 
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Introduction 
Ductal carcinoma in situ (DCIS) is considered a non-obligate precursor of invasive breast 
cancer of ductal/no special type (IDC) as many IDCs have evidence of associated DCIS at 
presentation [1],[2] and the two components have similar genetic changes, suggesting that in 
the majority of cases the invasive component has arisen from the DCIS [3]. Synchronous DCIS 
is more frequent in luminal and HER2 positive IDC (53% and 63% respectively) than invasive 
basal breast cancer (33%) [4]. Since the introduction of screening mammography there has 
been an increase in the reported incidence of pure DCIS with no invasive component [5], with 
about 20% of screen-detected tumors being pure DCIS [6]. 
 
Most non-genetic risk factors for breast cancer have similar associations with DCIS and IDC, 
again supporting the notion that DCIS is a precursor of invasive cancer [7, 8]. Epidemiological 
studies have shown there is an inherited predisposition to DCIS, with women with DCIS being 
2.4-times more likely to have an affected mother and sister with breast cancer than controls 
[9]. One study of almost 40,000 women suggested that the familial relative risk of DCIS maybe 
greater than that of invasive breast cancer [10], but this was not confirmed in the Million 
Women Study, which showed a similar association with family history for DCIS and IDC [8]. 
 
The familial risk associated with invasive breast cancer is in part explained by both high risk 
rare variants and low-risk susceptibility loci. We have shown that the majority of low-risk 
invasive breast cancer predisposition loci also predispose to DCIS and, as for invasive 
disease, different loci predispose to ER positive and ER negative DCIS and high and low 
grade DCIS [11]. However, the frequency of pathogenic high and moderate risk variants in 
DCIS is not clear. Claus et al studied 369 women (mean age 53.8 years) with pure DCIS  
selected from a case control study of carcinoma in situ and found that 2.4% had pathogenic 
variants in BRCA2 and 0.8% in  BRCA1 [12]. Hall et al analysed a highly selected cohort of 
women with carcinoma in situ (LCIS and DCIS) that were referred to Myriad for genetic testing. 
They found that 5.2% of women with pure carcinoma in situ (CIS) had BRCA1/2 mutations 
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(2.3% if women with a family history of breast cancer were excluded) and like Claus et al, that 
BRCA2 mutations were more common than BRCA1 [13]. Both these studies were performed 
before gene panel genetic testing was available and therefore other breast cancer 
predisposition genes such as PALB2, CHEK2 and TP53 were not assessed. 
 
In this study we report the frequency of rare variants in five known breast cancer 
predisposition genes (BRCA2, BRCA1, TP53, CHEK2, and PALB2) in 655 cases of pure 
DCIS with no invasive disease in women diagnosed before the age of 50. These cases were 
included in our previous study of low risk susceptibility loci in DCIS [11]. 
 
Methods 
Samples 
655 cases of pure DCIS with no invasive disease diagnosed in women aged under 50 were 
included in this study, Table 1. The majority of cases (633) were recruited through the 
ICICLE study (MREC 08/H0502/4) from 95 hospitals throughout the UK. This study was set 
up with the specific aim of investigating genetic predisposition to DCIS in the UK. A further 
22 cases were recruited through the King’s Health Partners (KHP) Cancer Biobank (NHS 
REC ref. 12-EE-0493). Samples from patients under the age of 50 were selected for this 
analysis in order to enrich for cases likely to have a genetic component to their disease. 
 
All controls were collected through the ICICLE and GLACIER studies (a similar study of 
lobular breast cancer, MREC 06/Q1702/64) and were identified by asking patients (cases) 
from both studies at the time of recruitment to identify female non-blood relatives or friends 
who were willing to donate a blood sample. These healthy volunteers were only eligible if 
they had no personal or family (up to 2nd degree) history of invasive breast cancer, lobular 
carcinoma in situ (LCIS), DCIS or of benign breast disease. Controls were not age matched 
and could be of any age, although older individuals were preferred (super-controls), as they 
had lived through many of their at-risk years.  
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All participants (cases and controls) donated a blood sample and were asked to complete a 
self-administered paper-based questionnaire on their family history. 
 
Data on grade and estrogen receptor (ER) status was ascertained mostly from the hospital 
pathology reports. In 200 cases where the grade data was missing from the report but a 
tumor block was available, a H&E section was cut and the DCIS was graded by the study 
histopathologist (SEP) according to UK and CAP guidelines [14].  A subset of 81 cases, 
graded in the pathology report and with a tumour block available, were examined to assess 
the reliability of the cytonuclear grade provided by the pathology reports. In the majority of 
cases (86.5%) grade was concordant with the pathology report. Nine cases were re-graded 
as low/intermediate grade and two cases as high grade. As the study pathologist re-graded 
the samples on a single H&E section, rather than all the blocks from an individual case, and 
in some cases on re-excision specimens with residual disease rather than the original 
excision specimen, the grade reported in the pathology report, if available, was used for the 
purposes of this study. 
 
If ER status was not  available from the local histopathology report and the tumor block was 
available, immunohistochemistry was performed and scored using the Allred method as 
previously described [11]. An Allred score of 3 or more was considered ER+ and that with 
scores of 0-2 (approximately equivalent to less than 1% of nuclei) were regarded as ER-.  
 
Next-Generation Sequencing 
After DNA extraction from peripheral blood, Access Array technology (Fluidigm) was used to 
amplify all exons of BRCA2, BRCA1, TP53, CHEK2 and PALB2 using a custom made 
targeted sequencing panel consisting of 321 amplicons (Additional File 1). The Fluidigm 
designed primers were supplied in single-plex with forward and reverse primers combined, 
these were multiplexed according to supplier’s instruction to achieve optimal efficiency. 
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Purified libraries were quantified using Qubit High Sensitivity Assay Kit and their average 
length size was measured in Tapestation using the D1000 screentape. The quantity and 
length size values obtained from the readings were used to calculate the final Molar 
concentration in order to prepare each sequencing library at 4nM containing 960 samples, 
based on the following formula: 
𝑀𝑜𝑙𝑎𝑟 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑖𝑛 𝑛𝑀) = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑖𝑛 𝑛𝑔)𝑥106𝑥(
1
649
)𝑥(
1
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑖𝑧𝑒 (𝑖𝑛 𝑏𝑝)
) 
All quantified libraries were subsequently sequenced on a HiSeq2500 (Illumina). 
 
Bioinformatics Analysis 
Primer sites from the amplicons were trimmed using Btrim and then sequences were aligned 
to the reference genome (http://www.novocraft.com, GRCh37 version) using Novoalign (Gap 
opening penalty = 65 and gap extension penalty = 7 thresholds were applied). Picard tools 
(v1.74 https://github.com/broadinstitute/picard) and Bedtools (v2.17.0) were used to assess 
coverage. Variant calling was performed using Samtools and annotated using the Annovar 
tool [15]. We optimised the calling based on a set of variants that were positive controls and 
samtools was the optimal caller compared to HaplotypeCaller from GATK. The transcript 
that was used for each gene is reported in Additional File 1. The frequency of variant alleles 
from European reference populations was obtained from three sources (1000 genomes, 
ESP, ExAC), Additional File 2. 
 
Variants were further filtered based on read depth, quality score, and genotypic quality. All 
variants with a read depth < 10, quality score < 20, or genotypic score < 20 were excluded 
from the analysis. In addition, variants with an allelic ratio < 0.2 were excluded irrespective of 
read depth and variants with an allelic ratio < 0.3 and read depth < 50 were also removed. 
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 Variants that had been previously clinically evaluated and deposited in the ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar/) were assigned labels of benign, variants of unknown 
significance (VUS), conflicting or pathogenic, as per ClinVar. 
 
Variants not present in the ClinVar database were considered pathogenic if they were 
predicted to lead to protein truncation (frameshift indels, stop-gain, stop-loss or intronic 
variants within 2 base pairs of the splicing junction; Additional File 3) and variants unknown 
significance (VUS) if they were nonsynonymous substitutions or in-frame indels. Novel 
variants in the last exon of a gene meeting the above criteria of pathogenic were not 
excluded as, although unlikely to result in loss of function through nonsense mediated 
decay, these variants may have substantial impact on the protein product. However, no such 
variants were detected in this study. 
To further investigate the importance and validity of our findings, we used an external 
resource of controls. A non-Finnish European population of controls from gnomAD (gnomAD 
controls v2.1) was used as a replication control cohort. 
 
Statistical analysis 
Fisher’s exact test was used for gene based rare variant analysis for both case control and 
case only analyses. One sided test was selected since the expectation was enrichment 
rather than deficit of variants in cases over controls. No adjustments have been made to 
account for multiple testing. With the current sample size, we have ~80% power (alpha 
=0.05) to detect variants of combined allele frequency =0.001 and an effect size of OR = 5. 
 
Validation 
All putative pathogenic alleles identified by the above methods were confirmed by Sanger 
sequencing. 
 
Assessment of Copy Number Variation 
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Two bioinformatics tools were used to assess copy number variation (CNV) in our 
sequencing data: CNVkit version 0.9.5 [16] and ONCOCNV version 6.9 [17].  The first, 
CNVkit, , running in amplicon sequencing mode, was used to identify exon-level copy 
number variations using on-target coverages alone. 1611 control samples were used to 
construct a reference copy number profile, and the default circular binary segmentation 
(CBS) algorithm was used to derive segments. The second, ONCOCNV, is a package 
specifically designed for amplicon sequencing data. Fifteen randomly selected control 
samples were used to construct the reference copy number profile, and the default cghseg 
algorithm was used to derive segments. All CNVs detected by these methods underwent 
multiplex ligation-dependent probe amplification (MLPA) using MRC Holland kits 
(https://www.mlpa.com/) in order to validate the finding. DNA samples were amplified 
and PCR products were analysed on the ABI 3730 Genetic Analyser (Applied 
Biosystems) using TAMRA 500, as per the manufacturers instructions. Coffalyser 
(MRC Holland)  was used to call exonic deletions / rearrangements. 
 
Results 
The analysis was performed on 655 cases of pure DCIS with no invasive disease diagnosed 
in women aged under 50, together with 1,611 controls. The median age of cases was 45 
years (interquartile range 6) and of controls was 52 (interquartile range 12),  Data on grade 
and estrogen receptor (ER) status were available for 98% and 73% of the cases in the 
study, respectively, Table 1.  
 
The mean coverage of our target region was 800 reads across all samples, with an average 
of at least 40 reads for more than 98% of the target region per sample. Of the 321 amplicons 
analysed seven failed to amplify consistently across the majority of the samples, however 
even for these seven the majority of samples had at least 10 reads for 90% of the amplicon, 
and there was no difference in amplification between cases and controls, Additional File 4. 
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No exon-level CNVs were identified using CNVkit version 0.9.5. Thirteen copy number 
variants across 8 samples were detected by ONCOCNV, however none were confirmed 
using MLPA, Additional File 5.  
 
We found an association with DCIS and pathogenic variants in BRCA2, CHEK2, PALB2, 
BRCA1 and TP53, Table 2 ( individual raw data, Additional File 2).  
 
BRCA2  
The strongest association was with BRCA2 (OR = 27.96, 95%CI 6.56-119.26, P = 2 x10-10), 
Table 2, Figure 1a. Of the 22 pathogenic variants identified, all had been previously 
described apart from a novel frameshift in exon 11 (c.5754dupT:p.H1918fs). 50% of 
pathogenic variants occurred in exon 11. Only two pathogenic variants occurred in more 
than one patient: exon20:c.8575delC:p.Q2859fs in two patients and 
exon25:c.C9382T:p.R3128X in two patients, Additional File 6. 95% of the cases with a 
pathogenic variant in BRCA2 had high or intermediate grade DCIS and, in the 15 cases 
where ER status was known, all were ER positive. There was also an association with age < 
40 years (OR = 4.12,  95%CI 1.75-9.69, P = 0.003), Table 3, and family history  of breast 
cancer in a first degree relative  (OR = 4.29, 95%CI 1.82-10.08, P = 0.001), Table 4. 
 
CHEK2 
CHEK2 also showed a strong association with DCIS (OR = 8.04, 95%CI 2.93-22.05, P = 9 
x10-6), but with a smaller effect size than BRCA2, Table 2, Figure 1b. Of the 16 pathogenic 
variants detected, 13 were the c.1100delC mutation.  The remaining three variants were 
novel frameshift mutations, one in exon 3: c.401_402del, and two in exon 12: c.1262delT 
and c.1368dupA, Additional File 7.  Again, all were high or intermediate grade DCIS and, of 
the 14 with known ER status, 12 were ER positive. There was no association with age <40 
(81% of cases occurred in the 40-49 age group) or family history, Tables 3 and 4. 
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PALB2 
There was an association with PALB2 (OR 14.88, 95%CI 1.79-123.88, P = 0.003), Table 2 
but this was weaker than that for BRCA2 and CHEK2. Of the six pathogenic PALB2 variants 
detected, three were novel frameshifts (two in exon 4, one in exon 5, Figure 1c, Additional 
File 8). Of the three known, two were in exon 10 (rs180177132), which has previously been 
shown to be associated with breast cancer (OR = 4.21, 95%CI 1.85-9.61), but with no 
evidence of a differential association with ER status [18]. All women with PALB2 pathogenic 
variants had high or intermediate grade DCIS and were ER positive. There was no 
association with age <40, but there was an association with family history of breast cancer in 
a first degree relative (OR = 14.37, 95%CI 1.68-123.25, P = 0.006), Table 4. 
 
BRCA1 
There were four DCIS cases that were found to harbor pathogenic BRCA1 germline variants 
and no controls ((P = 0.007), Table 2, Additional File 9.  One was the well described 
exon12:c.C4327T:p.R1443X, the other three were novel frameshift mutations, two in exon 
11 and one in exon 3. Three were ER negative (one unknown) and three high grade DCIS. 
There was no association with age <40 and a borderline association with family history of 
breast cancer in a first degree relative (P = 0.058). Three of the cases had a family history of 
breast and or ovarian cancer in first degree relatives under the age of 50. However, the case 
with the novel frameshift variant in exon 10: c.3750delG:p.E1250fs had a strong family 
history of other cancers (cervical, lung, oral) but not breast.  
 
TP53 
There were three DCIS cases that were found to harbor pathogenic TP53 germline variants 
and no controls ((P = 0.02), Table 2. Two were stopgain variants (one novel) and the other a 
nonsynomous variant (rs397514495) considered pathogenic in the literature [19], but 
recently suggested to be a VUS as it does not disrupt all the functions of TP53 just 
apoptosis[20], Additional File 10a. The women that carried these variants did not meet the 
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criteria for classic Li-Fraumeni or Li-Fraumeni-like syndrome. The novel stopgain variant 
(NM_000546:exon4:c.G272A:p.W91X) was found in a woman with bilateral DCIS at age 35 
and a first degree relative with breast cancer < 40 years, but no other cancers. The other 
known stopgain variant was identified in a woman with DCIS at age 40 whose father 
developed an unknown cancer age 50 but with no other family history of cancer. The 
missense variant occurred in a woman with DCIS age 45 and a family history of breast 
cancer in second degree relative aged 60, but no other cancers. Again, all had intermediate 
or high grade DCIS, with 2 ER positive, 2 ER negative (in the bilateral case one side was ER 
positive and the other ER negative). 
 
As most pathogenic germline mutations in TP53 are missense rather than truncating 
mutations [21] it is possible that by only considering  novel variants as pathogenic if they 
were predicted to lead to protein truncation we may have missed novel pathogenic missense 
variants in TP53. We therefore looked at these in more detail. Only one novel missense 
variant was detetcted, NM_000546:exon10:c.G1054T:p.D352Y, and this was in a control.  
Three variants called as VUS in the ClinVar database were identified in cases, Additional 
File 10b. One, NM_000546:exon8:c.G869A:p.R290H is listed in the IARC TP53 database 
[22] as being associated with Li Fraumeni like syndrome, and in our study was found in one 
case and two controls.   
 
Biallelic Mutation Carriers 
There were four patients carrying two pathogenic variants in different genes. All had a family 
history of cancer and three a family history of breast cancer, Additional File 11. 
 
Bilateral and subsequent invasive disease 
Metachronous bilateral disease was most commonly found in CHEK2 mutation carriers with 
5/16 (31%) developing subsequent contralateral disease after a diagnosis of unilateral DCIS 
(in two this was in the form of invasive disease, in two LCIS and in one DCIS) compared to 
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2/22 (9%) for BRCA2. The latter, however, will be influenced by the fact that nine of the 
BRCA2 carriers elected for bilateral prophylactic mastectomies based on their family history 
or the results of genetic testing (five underwent genetic testing). As this study does not have 
long term follow up data it was not possible to assess whether germline pathogenic variants 
were associated with subsequent invasive recurrence of DCIS. 
 
Variants unknown significance  
Analysis of variants unknown significance (VUS), either known or novel, revealed no excess 
of VUS in for BRCA2, PALB2, TP53 or BRCA1, Additional File 12. A VUS in exon 4 of 
CHEK2 (rs77130927, c.C538T:p.R180C), which we have previously shown to have a 
borderline association with invasive lobular cancer (ILC) (P = 0.03, Petridis et al, accepted 
Cancer Epidemiology, Biomarkers & Prevention) was found in two DCIS cases and one 
control.  
 
Discussion 
Early data on women with BRCA1 and BRCA2 mutations suggested that presentation as 
pure DCIS was infrequent. However, Yang et al showed that ~60% of BRCA1 and 2-
associated invasive tumors had associated DCIS of similar phenotype [23]. They also found  
that the number of pure DCIS cases was similar in BRCA1 and BRCA2 mutations carriers 
(21% vs 23%), in contrast to Krammer et al who reported that pure DCIS was more frequent 
in BRCA2 mutation carriers compared to BRCA1 carriers (5%, 36/246, versus 9%, 23/250, P 
= 0.0026). [24]. In our study of sporadic pure DCIS, pathogenic BRCA2 variants were far 
more common than BRCA1 mutations (3.5% vs 0.6%). This is similar to the data of Claus et 
al [12] who found that 2.4% had pathogenic variants in BRCA2 and 0.8% in BRCA1 in a 
slightly older group of DCIS patients (mean age 53.8 years). Similarly Hall et al found that 
5.2% of women under 50 years of age with carcinoma in situ (LCIS and DCIS) had BRCA1/2 
mutations, with BRCA2 mutations being more common than BRCA1 [13]. 
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We found that BRCA2 mutations occurred in 2.4% of DCIS in women under the age 50 and 
in 9% under the age of 40. All but one of these variants had been previously described in 
invasive breast cancer. Of the genes studied BRCA2 was the only gene where pathogenic 
mutations were associated with younger age. All the cases of DCIS in BRCA2 carriers were 
ER positive (where ER status was known), unlike invasive disease where only 77% are ER 
positive [25]. In contrast BRCA1 pathogenic variants were infrequent, four in total (only one 
had been previously described), and associated with predominantly ER negative DCIS. 
 
Pathogenic variants  in CHEK2 were the second most common set of mutations after 
BRCA2 and occurred in 2.5% of pure DCIS under the age of 50. Unlike BRCA2 there was 
no association with age  and the majority were the well described c.1100delC variant. There 
was no evidence of an association with the rare missense variant p.I157T (c.T470C, 
rs17879961), which was found in three controls and no cases. This high frequency of 
CHEK2 variants in pure DCIS has not been previously described, although Schmidt et al 
noted in their study of tumour characteristics in CHEK2 c.1100delC carriers, that carriers 
from population- and hospital-based studies more often developed in situ tumors (LCIS and 
DCIS) compared to carriers from familial or clinical genetics center–based studies; this was 
interpreted as a bias estimate due differential recruitment related to family history of breast 
cancer and screening [26]. Our findings are also supported by Couch et al who reported 
data on the frequency of CHEK2 mutations in a series of breast cancer with and without 
pure DCIS allowing one to determine mutation rates in pure DCIS cases. In that study 2.87% 
of  DCIS cases had  pathogenic CHEK2 variants compared to 1.43% in invasive disease 
[27].  
 
The tumour phenotypes associated with PALB2 tumours are very similar to those associated 
with BRCA2 tumours, with 61% of invasive tumours having associated DCIS [28]. It is 
therefore not surprising that we have found PALB2 pathogenic mutations in women with 
pure DCIS and that they are more common in women with a first degree relative with breast 
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cancer. However unlike BRCA2 they were not associated with age <40 years, this is 
supported by the findings of Antoniou et al. who showed there was a constant relative risk, 
irrespective of age, for pathogenic variants in PALB2 [29]. The frequency of PALB2 variants 
in our data is supported by the study by Couch et al where one can infer from the 
supplementary data that the frequency of pathogenic PALB2 variants in DCIS is 0.96% [27]. 
 
Pure DCIS (73% HER2 positive, 55% ER positive) and high grade comedo DCIS have been 
described in Li-Fraumeni Syndrome [30, 31]  but our data show that TP53 mutations are 
infrequent in sporadic DCIS. Although two of three pathogenic variants identified had been 
previously described, none of the women had a family history of cancer to suggest Li-
Fraumeni Syndrome (LFS).This may be because they are de novo mutations or because 
two were loss of function mutations which often do not have such a typical LFS 
phenotype as dominant negative missense mutations [32]. The known missense mutation 
detected has been shown to be associated with Li-Fraumeni Like Syndrome rather than true 
LFS [22]. 
 
The odds ratios presented in this study are higher than those previously reported for these 
genes in invasive disease.  This likely due to the size of the study which is too small to yield 
stable estimates of associations with DCIS, but does give useful estimates of prevalence 
and, of note, is twice as large as the study by Claus et al., the only other study documenting 
the prevalence of BRCA1/2 mutations in sporadic DCIS. The other reason is due to the use 
of older controls. When we compare our cases to 21,384 non-Finnish European controls 
from gnomAD (gnomAD controls v2.1, http://gnomad.broadinstitute.org ) we see the the 
odds ratios fall to similar levels previously reported for invasive cancer with the exception of 
CHEK2 (OR=3.69, 95%CI.19-6.23) which still remains higher than that reported in studies of 
invasive breast cancer (OR~2), Table 2. Schmidt et al. also found this in their large series 
from the Breast Cancer Association Consortium (invasive: OR = 2.4, 95%CI 2.04-2.82, in 
situ: OR = 3.53, 95%CI 2.38-5.23) [26]). We also found a similar finding in lobular cancer 
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where LCIS had a stronger association with CHEK2 mutations than ILC (ILC OR = 4.29, 
95%CI 1.60-11.51, P = 0.0017; LCIS OR = 9.95, 95%CI 3.44-28.82, P = 5 x10-5, Petridis et 
al. accepted Cancer Epidemiology, Biomarkers & Prevention). This suggests that CHEK2 
pathogenic variants may be predisposing to the in situ stage of breast cancer with some not 
progressing to the invasive state.   
 
In a study of 6478 patients with invasive breast cancer under the age of 50 Schmidt et al [33] 
found a higher frequency of  BRCA1 mutations compared to our study of DCIS (3.2% versus  
0.6%). We believe that this difference in frequency of BRCA1  mutations stems from the fact 
that the vast majority of the samples in our study are ER+ and only 13% of the samples are 
ER-, compared to 25% in the invasive study of Schmidt et al. 
 
There is currently debate as to the need for mutation screening in women with DCIS. In this 
study 7.2% of women with DCIS (irrespective of ER status) under the age of 50 had 
pathogenic variants in one of five known breast cancer predisposition genes. This level does 
not reach the current UK threshold for genetic testing  
(https://www.nice.org.uk/guidance/cg164/chapter/Recommendations#genetic-testing), 
however women under 40 years of age had a 13% (11% excluding CHEK2 variants) 
probability of having a germline mutation which does reach the UK threshold of 10% for 
routine testing. For women under 40 years of age with a family history of breast cancer the 
frequency of germline mutations increases to 21%. 
 
There has been particular focus on ER negative DCIS and whether these women should 
undergo HER2 testing and, if this is also negative, be offered BRCA1 and BRCA2 testing, as 
is recommended for those with triple negative invasive breast cancer. Unfortunately, in our 
series we did not have data on HER2 receptor status as it is not routinely assessed in cases 
of DCIS in present clinical practice. However, looking solely at  ER negative DCIS, only 9% 
under the age of 50 and 8% under the age of 40 had pathogenic variants and these were in 
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BRCA1, TP53 and CHEK2. These figures rise to 16% and 11% respectively if only women 
with a family history of breast cancer are considered, Table 5a. In contrast the frequency of 
pathogenic variants in ER positive DCIS under the age of 40 was much higher; 9% of 
women under the age of 50 had pathogenic variants rising to 29% under the age of 40 (14% 
and 42% respectively if only women with a family history of breast cancer are considered) 
Table 5b. 
 
Conclusions  
This study has shown that a DCIS associated malignant pathway can occur in patients who 
have pathogenic variants in BRCA2, CHEK2, PALB2, BRCA1 and TP53. We also show that 
the focus of genetic testing should be on ER positive, intermediate and high grade DCIS 
from patients under the age of 40, rather than ER negative DCIS, although restricting such 
testing to those age under 40 would fail to identify the majority of CHEK2 and PALB2 
mutation carriers. Once mutations are identified in these women, chemoprevention with 
tamoxifen and surveillance is a potential alternative to prophylactic mastectomy, particularly 
in CHEK2 carriers where the risk of invasive disease is less. Further studies with long term 
follow up data are required to ascertain whether these germline pathogenic variants identify 
a subgroup of DCIS that are more likely to progress to invasive disease or whether somatic 
changes in the DCIS are a more important predictor of recurrence. 
 
 
 
 
 
 
 
 
 
 17 
DECLARATIONS 
Funding 
This work was supported by a King’s Health Partner’s Research and Development 
Challenge Fund (R150505), a Breast Cancer Campaign Project Grant (2011NovPR49) and 
the National Institute for Health Research (NIHR) Biomedical Research Centre based 
at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views 
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health. Sample collection was funded by a CRUK Project grant (8873). 
 
Acknowledgements 
We thank all the individuals who took part in this study and all the clinicians, technicians and 
administrative staff who have enabled this work to be carried out.  In particular, we thank: 
Maria Troy, Kelly Kohut and Pat Gorman. 
Ethics approval and consent to participate. 
All patients and controls were recruited through the following ethically approved studies and 
gave consent to genetic testing (GLACIER study, MREC 06/Q1702/64; ICICLE, MREC 
08/H0502/4; King’s Health Partners breast tissue bank, NHS REC ref. 12-EE-0493) 
Consent for publication 
Not applicable 
 
Availability of data and materials 
The dataset supporting the conclusions of this article can be found in the additional data 
(Additional File 2). 
Conflict of interest 
The authors declare that there is no conflict of interest. 
 18 
 
Author’s contributions 
EJS conceived the study and wrote the manuscript. 
CP performed all the next generation sequencing, under the supervision of MAS  
CP and IA performed the analysis, under the supervision of MAS 
VS performed the Sanger sequencing 
CM, AM, AC and CG collected and provided samples and questionnaire data 
SP reviewed histology of samples 
EJS, IT and RR set up the GLACIER and ICICLE studies 
All authors reviewed the manuscript  
 
List of Abbreviations 
DCIS - ductal carcinoma in situ 
IDC - invasive ductal cancer 
LCIS - lobular carcinoma in situ 
ILC - invasive lobular cancer 
DCIS - ductal carcinoma in situ 
IDC - invasive ductal cancer 
OR - odds ratio 
95 CI - 95% confidence interval 
VUS - variant of unknown significance 
 
  
 19 
References: 
 
 
1. Wong H, Lau S, Yau T, Cheung P, Epstein RJ: Presence of an in situ component 
is associated with reduced biological aggressiveness of size-matched invasive 
breast cancer. British journal of cancer 2010, 102(9):1391-1396. 
2. Ruszczyk M, Zirpoli G, Kumar S, Bandera EV, Bovbjerg DH, Jandorf L, Khoury T, 
Hwang H, Ciupak G, Pawlish K et al: Breast cancer risk factor associations differ 
for pure versus invasive carcinoma with an in situ component in case-control 
and case-case analyses. Cancer Cause Control 2016, 27(2):183-198. 
3. Kim SY, Jung SH, Kim MS, Baek IP, Lee SH, Kim TM, Chung YJ, Lee SH: Genomic 
differences between pure ductal carcinoma in situ and synchronous ductal 
carcinoma in situ with invasive breast cancer. Oncotarget 2015, 6(10):7597-
7607. 
4. Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, Liang R, Epstein RJ, Yau T: 
Coexisting ductal carcinoma in situ independently predicts lower tumor 
aggressiveness in node-positive luminal breast cancer. Medical oncology 
(Northwood, London, England) 2012, 29(3):1536-1542. 
5. Li CI, Daling JR, Malone KE: Age-specific incidence rates of in situ breast 
carcinomas by histologic type, 1980 to 2001. Cancer Epidem Biomar 2005, 
14(4):1008-1011. 
6. Leonard GD, Swain SM: Ductal carcinoma in situ, complexities and challenges. 
Journal of the National Cancer Institute 2004, 96(12):906-920. 
7. Claus EB, Stowe M, Carter D: Breast carcinoma in situ: risk factors and 
screening patterns. Journal of the National Cancer Institute 2001, 93(23):1811-
1817. 
8. Reeves GK, Pirie K, Green J, Bull D, Beral V, Million Women Study C: Comparison 
of the effects of genetic and environmental risk factors on in situ and invasive 
ductal breast cancer. Int J Cancer 2012, 131(4):930-937. 
9. Claus EB, Stowe M, Carter D: Family history of breast and ovarian cancer and 
the risk of breast carcinoma in situ. Breast cancer research and treatment 2003, 
78(1):7-15. 
10. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V: Comparison of risk 
factors for ductal carcinoma in situ and invasive breast cancer. Journal of the 
National Cancer Institute 1997, 89(1):76-82. 
11. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, 
Orr N, Cox A et al: Genetic predisposition to ductal carcinoma in situ of the 
breast. Breast cancer research : BCR 2016, 18(1):22. 
12. Claus EB, Petruzella S, Matloff E, Carter D: Prevalence of BRCA1 and BRCA2 
mutations in women diagnosed with ductal carcinoma in situ. Jama 2005, 
293(8):964-969. 
13. Hall MJ, Reid JE, Wenstrup RJ: Prevalence of BRCA1 and BRCA2 mutations in 
women with breast carcinoma In Situ and referred for genetic testing. Cancer 
prevention research 2010, 3(12):1579-1585. 
14. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, 
Kleer C, O'Malley FP, Page DL et al: Protocol for the examination of specimens 
from patients with invasive carcinoma of the breast. Archives of pathology & 
laboratory medicine 2009, 133(10):1515-1538. 
15. Hintzsche JD, Robinson WA, Tan AC: A Survey of Computational Tools to 
Analyze and Interpret Whole Exome Sequencing Data. Int J Genomics 2016, 
2016:7983236. 
16. Talevich E, Shain AH, Botton T, Bastian BC: CNVkit: Genome-Wide Copy Number 
Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 
2016, 12(4):e1004873. 
 20 
17. Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, 
Servant N, Gestraud P, Rio Frio T et al: Multi-factor data normalization enables 
the detection of copy number aberrations in amplicon sequencing data. 
Bioinformatics 2014, 30(24):3443-3450. 
18. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A: Bilateral 
risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of 
surveillance, epidemiology, and end results data. J Clin Oncol 2005, 
23(24):5534-5541. 
19. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P: The IARC TP53 
database: new online mutation analysis and recommendations to users. 
Human mutation 2002, 19(6):607-614. 
20. Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, Aston M, 
Esterling L, Manley S, Ross T: Prevalence of Variant Reclassification Following 
Hereditary Cancer Genetic Testing. Jama 2018, 320(12). 
21. Olivier M, Hollstein M, Hainaut P: TP53 mutations in human cancers: origins, 
consequences, and clinical use. Cold Spring Harb Perspect Biol 2010, 
2(1):a001008. 
22. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M: TP53 
Variations in Human Cancers: New Lessons from the IARC TP53 Database and 
Genomics Data. Human mutation 2016, 37(9):865-876. 
23. Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang 
PJ, Czerniecki BJ: DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, 
phenotype, and expression of oncodrivers C-MET and HER3. J Transl Med 
2015, 13:335. 
24. Krammer J, Pinker-Domenig K, Robson ME, Gonen M, Bernard-Davila B, Morris EA, 
Mangino DA, Jochelson MS: Breast cancer detection and tumor characteristics 
in BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment 
2017, 163(3):565-571. 
25. Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green 
AJ, Bracken A, Geraghty JG: Phenotypic analysis of familial breast cancer: 
comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial 
breast cancer. European journal of surgical oncology : the journal of the European 
Society of Surgical Oncology and the British Association of Surgical Oncology 2015, 
41(5):641-646. 
26. Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers 
H, Waisfisz Q, Hollestelle A, Schutte M et al: Age- and Tumor Subtype-Specific 
Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 2016, 
34(23):2750-2760. 
27. Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, 
Thomas A, Lilyquist J et al: Associations Between Cancer Predisposition Testing 
Panel Genes and Breast Cancer. Jama Oncol 2017, 3(9):1190-1196. 
28. Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, 
Mitchell G, Trainer AH, Lindeman GJ et al: Tumour morphology predicts PALB2 
germline mutation status. British journal of cancer 2013, 109(1):154-163. 
29. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, 
Subramanian D, De Leeneer K, Fostira F et al: Breast-cancer risk in families with 
mutations in PALB2. The New England journal of medicine 2014, 371(6):497-506. 
30. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford 
JM, Euhus D, Lebensohn A et al: Breast cancer phenotype in women with TP53 
germline mutations: a Li-Fraumeni syndrome consortium effort. Breast cancer 
research and treatment 2012, 133(3):1125-1130. 
31. Evans DG, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F: 
Long-term outcomes of breast cancer in women aged 30 years or younger, 
based on family history, pathology and BRCA1/BRCA2/TP53 status. British 
journal of cancer 2010, 102(7):1091-1098. 
 21 
32. Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fermey P, Belotti M, 
Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugières L et al: Revisiting Li-
Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 2015, 
33(21):2345-2352. 
33. Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, 
Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ et al: Breast Cancer 
Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of 
Young Women. Journal of the National Cancer Institute 2017, 109(8). 
 
 
  
 22 
TABLE LEGENDS 
Table 1: ER status and grade of DCIS by age. 
 
Table 2: Association of known pathogenic variants and DCIS in women <50 years of age by 
gene. For the GnomAD comparison, Non-Finnish European controls were used (v2.1). 
 
Table 3: Case only analysis of pathogenic variants in DCIS by age. 
 
Table 4: Case only analysis of pathogenic variants in DCIS for family history of breast 
cancer. 
 
Table 5a: Frequency of pathogenic variants in ER positive DCIS by age. 
Table 5b: Frequency of pathogenic variants in ER negative DCIS by age. 
 
 
FIGURE LEGEND 
Figure 1: Position of pathogenic variants in DCIS cases in 
(a) BRCA2, (b) CHEK2, (c) PALB2, (d) BRCA1  
 
ADDITIONAL FILES 
Additional File 1: Targeted Sequencing Panel 
Additional File 2: Coverage data for all pathogenic variants identified 
Additional File 3: Definition of variants 
Additional File 4: Amplicons that failed to amplify consistently 
Additional File 5: Copy number variation detected by ONCOCNV 
Additional File 6: BRCA2 pathogenic variants in cases 
Additional File 7: CHEK2 pathogenic variants in cases 
Additional File 8: PALB2 pathogenic variants in cases 
Additional File 9: BRCA1 pathogenic variants in cases 
 23 
Additional File 10a: TP53 pathogenic variants in cases  
Additional File 10b: TP53 VUS in cases 
Additional File 11: Age of onset of DCIS and family history details of women with two 
pathogenic variants in different genes 
Additional File 12: Frequency of Variants of Unknown Significance and DCIS in women <50 
years of age by gene 
 
 
 
 
 
  
 24 
 
Table 1: ER status and cytonuclear grade of DCIS by age. 
 
Age Total ER+ ER- ER  
unknown 
High 
Grade 
Int  
Grade 
Low 
Grade 
Grade 
unknown 
40-49 555 345 
(62%) 
62 
(11%) 
 
148 
(27%) 
 
345 
(62%) 
 
148 
(27%) 
 
47 
(8%) 
 
15 
(3%) 
 
<40 100 45 
(45%) 
26 
(26%) 
 
29 
(29%) 
 
72 
(72%) 
 
20 
(20%) 
 
7 
(7%) 
 
1 
(1%) 
 
All  
 
655 390 88 177 417 168 54 16 
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Table 2: 
Association of known pathogenic variants and DCIS in women <50 years of age by gene. 
For the GnomAD comparison, Non-Finnish European controls were used (v2.1). 
 
Gene 
Pathogeni
c variants 
in cases 
(N=655) 
Pathogenic 
variants in 
controls 
(N=1,611) 
OR (95% CI) P value 
Pathogenic 
variants in 
gnomAD 
controls 
(N=21,384) 
OR (95% CI) 
(vs gnomAD 
controls) 
P value 
(vs 
gnomAD 
controls) 
BRCA2 22 (3.4%) 2 (0.1%) 27.96 (6.56-119.26) 2 x10-10 76 (0.35%) 9.74 (6.02-15.76) 1 x 10-13 
CHEK2 16 (2.4%) 5 (0.3%) 8.04 (2.93-22.05) 9 x10-6 144 (0.67%) 3.69 (2.19-6.23) 2 x 10-5 
PALB2 6 (0.9%) 1 (0.06%) 14.88 (1.79-123.88) 0.003 22 (0.1%) 8.98 (3.63-22.21) 1 x 10-4 
BRCA1 4 (0.6%) 0 (0%) inf 0.007 81 (0.38%) 1.62 (0.59-4.42) 0.32 
TP53 3 (0.5%) 0 (0%) inf 0.02 16 (0.07%) 6.14 (1.79-21.14) 0.018 
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Table 3: Case only analysis of pathogenic variants in DCIS by age. 
 
Gene 
Pathogenic 
variants in 
cases  
aged <40 
(N= 100) 
Pathogenic 
variants in 
cases aged 
40-49 
(N= 555) 
OR (95% CI) P value 
BRCA2 9 (9%) 13 (2.3%) 4.12 (1.75-9.69) 0.003 
CHEK2 3 (3%) 13 (2.3%) 1.29 (0.37-4.54) 0.72 
PALB2 1 (1%) 5 (0.9%) 1.11 (0.13-9.53) 1 
BRCA1 1 (1%) 3 (0.5%) 1.86 (0.19-17.90) 0.485 
TP53 1 (1%) 2 (0.4%) 2.79 (0.25-30.86) 0.39 
 27 
Table 4: Case only analysis of pathogenic variants in DCIS for family history of breast 
cancer. 
 
  
Carriers with FH of BC in first 
degree relative vs no FH  
Carriers with FH of  BC in 
any relative vs no FH 
Gene OR (95% CI) P OR (95% CI) P 
BRCA2 4.29 (1.82-10.08) 0.001 4.90 (1.65-14.54) 0.002 
CHEK2 0.93 (0.30-2.90) 1 1.76 (0.64-4.86) 0.32 
PALB2 14.37 (1.68-123.25) 0.006 5.27 (0.61-45.20) 0.12 
BRCA1 8.52 (0.88-82.07) 0.058 3.14 (0.33-30.26) 0.36 
TP53 1.40 (0.13-15.47) 1 2.09 (0.19-23.07) 0.62 
 
FH = family history 
BC = breast cancer  
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Table 5a: Frequency of pathogenic variants in ER negative DCIS by age. 
 
Gene Frequency 
under 40 years  
N = 26  
Frequency under 
40 years with FH* 
 N = 9 
Frequency under 
50 years  
N = 89  
Frequency under 
50 years with FH 
N = 38 
BRCA2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
CHEK2 1 (3.8%) 0 (0%) 3 (3.3%) 2 (5.2%) 
PALB2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
BRCA1 0 (0%) 0 (0%) 3 (3.3%) 3 (7.9%) 
TP53 1 (3.8%) 1 (11%) 2 (2.2%) 1 (2.6%) 
Total  
(% of ER- 
cases) 
2 (8%) 1 (11%) 8 (9%) 6 (16%) 
 
*FH= family history of breast cancer in any relative 
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Table 5b: Frequency of pathogenic variants in ER positive DCIS by age. 
 
Gene Frequency under 
40 years  
N = 45 
Frequency under 
40 years with FH* 
N = 24 
Frequency 
under 50 years 
N = 397 
Frequency under 
50 years with FH 
N = 197 
BRCA2 8 (17.8%) 7 (29.2%) 16 (4%) 14 (7.1%) 
CHEK2 2 (4.4%) 1 (4.2%) 12 (3%) 7 (3.6%) 
PALB2 1 (2.2%) 1 (4.2%) 5 (1.3%) 4 (2%) 
BRCA1 1 (2.2%) 0 (0%) 1 (0.3%) 0 (0%) 
TP53 1 (2.2%) 1 (4.2%) 2 (0.5%) 2 (1%) 
Total  
(% of ER+ 
cases) 
13 variants (29%) 
in  
11 women (24%)** 
10 variants (42%) 
in  
9 women (38%) 
36 variants (9%) 
in  
32 women (8%) 
27 variants (14%) 
in  
24 women (12%) 
 
*FH= family history of breast cancer in any relative 
** some individuals carry 2 variants 
 
 
